Day OneMonday, 19 May 2025 - ET (Eastern Time, GMT-05:00)

Deep dive into advanced topics related to your daily tasks and frustrations in your role:

• Breakdown of contract types and agreements
• Overview of contracting process and key stakeholders
• Basic pricing terminology and concepts (WAC, contract price, chargeback)
• Operational procedures for contract management
• Common chargeback errors

• End-to-end transaction flow explanation
• WAC to chargeback to final net price walkthrough
• System validations and checkpoints
• Manual vs. automated processes across major distributors
• Contract price update checklist and validation points

• Improve contracting and amendment efficiencies across your market access and pricing agreements with latest technology and AI innovations
• Demystify how natural language interactions and “machine conversations” will transform pricing, market access, and commercial team contract collaboration across the contract lifecycle
• Explain practical applications of generative AI for contract authoring, mass amendments, price changes, product launches, and managing complex financial terms and rebate structures
• How to leverage specialized AI Agent ecosystems to perform commercial work

Overview covering clinical trial phases, FDA approval pathways (fast track, PDUFA), fees, and how commercial/pricing considerations influence drug development.

• GPO roster management fundamentals
• Tools and processes for eligibility verification
• Managing mixed-use accounts and classifications
• 340B eligibility basics and compliance considerations
• Best practices for maintaining clean membership data

• Setting up initial commercial infrastructure
• Basic wholesaler agreement components
• NDC setup through first commercial ship
• Key operational considerations for new products/companies
• Common pitfalls and how to avoid them

Deep exploration of nuanced trade class determinations in gray areas and their cascading implications for government price reporting.

• Transformative therapeutics require extensive operational and financial planning as drugs move from "ancillary services" to central service lines
• Health system governance models evolving for drug selection in the therapeutic-centric era
• Need for concise data on volumes, site of care, length of stay, payer mix, and payment policies
• Reimbursement pressures and vertical integration of stakeholders forcing challenging negotiations and strategy discussions

Join us for this deep dive workshop into the everchanging active and pending SPTR laws from the legal and operational perspectives.

Join your industry colleagues during this 80 minute, informal and interactive roundtable discussion on your greatest barriers and pain points to drive results back at your organization.

• Operationalizing the IRA and Part D redesign implications
• SPTR and PDAB requirements
• PBM vertical integration
• Exponential 340B growth

20-minute blocks for Wholesalers and Manufacturers:

Who do you contact with questions for errors? Who do you contact when you need details on the process for filing this and that? Sign up your team to meet your contacts at some of the top wholesalers nationwide. These meet-and-greets are for connecting and learning the processes and needs for each stakeholder to work collaboratively together.

• Design cross-functional workflows integrating legal, pricing, regulatory and finance to maintain clear accountability for state reporting obligations
• Create comprehensive tracking systems for managing registrations, fees, reports and contacts
• Develop standardized processes for trade secret justifications and supporting documentation

• Gain immediate industry benchmarking through live polling on critical drug price transparency reporting requirements, with facilitated discussion revealing how peers navigate a range of topics, including new drug submissions for new NDCs of existing products, state requirements to report prices outside the US, approaches to reporting data elements when the information is not maintained or available in the regular course, among other hot topics
• Transform collective experiences into actionable compliance strategies through collaborative analysis of regulator interactions, submission challenges, and emerging best practices that address your organization's most pressing transparency compliance concerns

Updates directly from the manufacturers, vendors and CMS folks working to improve the health ecosystem from all sides. This industry group is here to answer questions on what they do, how they do it and what they are currently working on.

• Identifying contracting goals and aligning to organizational goals
• Examine contracting components and mechanisms
• Establish and monitor relevant outcomes
• Ensure success through appropriate roles,ccommunication and benchmarking

• Actions taken by drug manufacturers to address 340B double payment, utilization expansion, and the corresponding market responses
• The role of a neutral 340B clearinghouse as a solution, with demonstrated outcomes
• 340B Rebate Model = Neutral 340B Clearinghouse: A practical pathway to efficiently eliminate double payments, diversion, and manage utilization expansion
• Readiness to reconcile 340B paid claims with Maximum Fair Price (MFP) by maximizing the 340B clearinghouse to prevent duplicate payments and ensure proper utilization tracking
  
  

Who do you contact with questions for errors? Who do you contact when you need details on the process for filing this and that? Sign up your team to meet your contacts at some of the top wholesalers nationwide. These meet-and-greets are for connecting and learning the processes and needs for each stakeholder to work collaboratively together.